- Pfizer shares surged nearly 7%, their highest since January, after announcing a drug pricing deal with the U.S. government.
- The agreement involves sharp price cuts on some medications, a $70 billion U.S. investment from Pfizer, and a three-year exemption from pharmaceutical tariffs.
- Analysts at Bank of America and other firms said the deal’s financial impact on Pfizer should be minimal, describing it as largely symbolic.
- The Trump administration also launched TrumpRX, a platform to sell discounted drugs directly to consumers, alongside new Medicare price negotiation guidance.
- Retail investor sentiment remains very high for Pfizer, and its shares have risen 8.1% so far in 2025.
Pfizer shares climbed almost 7% on Wednesday after details emerged about a new drug pricing deal with the Trump administration. The agreement, announced Tuesday, includes large price reductions on several widely used medicines, a major U.S. investment plan by Pfizer, and a temporary exemption from proposed pharmaceutical tariffs.
According to company statements, Pfizer will cut prices on selected drugs by up to 100%, pledge $70 billion to expand its U.S. manufacturing presence, and secure a three-year waiver from new tariffs affecting pharmaceuticals. The statement also mentioned the launch of TrumpRX, a new government initiative for selling lower-cost drugs directly to consumers.
Analysts responded quickly to the announcement. Bank of America’s research division noted that while the timing was unexpected, many of the details had been anticipated. The firm stated, “both the White House and Pfizer statements lacked specifics and described the agreement as a loose set of measures unlikely to materially affect Pfizer’s earnings while giving the administration a political advantage.” The firm held a ‘Neutral’ rating with a $28 price target for the stock.
Other analysts shared similar views. Evan Seigerman of BMO Capital Markets suggested that the deal structure could guide other pharmaceutical companies, allowing cooperation with policymakers while avoiding strict pricing controls. Cantor Fitzgerald’s Carter Gould noted that the share price increase reflected relief that earnings guidance remained unchanged, while Raymond James analyst Chris Meekins argued that “the TrumpRX initiative was unlikely to reduce consumer costs unless paired with broader insurance reforms.”
The deal coincided with the release of the Trump administration’s final guidance for the third round of Medicare drug price talks, a process initiated under the Biden administration’s Inflation Reduction Act. The Centers for Medicare & Medicaid Services said the updated framework aims to be “more transparent, more workable for manufacturers, and more responsive to the needs of Medicare beneficiaries,” with negotiations for up to 15 additional drugs starting in 2026 and new pricing set for 2028. For more details, see Bloomberg’s report.
So far in 2025, Pfizer shares have gained 8.1%, with retail investors expressing strong optimism about the stock’s prospects.
Previous Articles:
- Alpaca Launches 24/7 Network for Instant Tokenization of US Stocks
- Ford Shares Surge as Q3 Sales Jump 8%, EV Deliveries Hit New High
- Bakkt Finalizes $11M Loyalty Unit Sale, Shares Drop, Bullish Chatter
- Top Bitcoin Miner Market Cap Soars Past $50B Amid AI Pivot
- Tornado Cash’s Roman Storm Seeks Acquittal After August Verdict
